4/14
10:44 am
gmab
Major Shareholder Announcement
Low
Report
Major Shareholder Announcement
4/14
06:22 am
gmab
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
Low
Report
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
4/13
09:35 am
gmab
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
Low
Report
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
4/9
01:01 pm
gmab
Genmab: Multiple Binaries Could Alter The Thesis [Seeking Alpha]
Low
Report
Genmab: Multiple Binaries Could Alter The Thesis [Seeking Alpha]
4/1
03:24 am
gmab
Major Shareholder Announcement
Low
Report
Major Shareholder Announcement
3/30
12:16 pm
gmab
Major Shareholder Announcement [Yahoo! Finance]
Low
Report
Major Shareholder Announcement [Yahoo! Finance]
3/30
11:59 am
gmab
Major Shareholder Announcement
Low
Report
Major Shareholder Announcement
3/27
08:02 am
gmab
Genmab A/S (GMAB) is now covered by Wolfe Research. They set an "outperform" rating and a $32.00 price target on the stock.
Low
Report
Genmab A/S (GMAB) is now covered by Wolfe Research. They set an "outperform" rating and a $32.00 price target on the stock.
3/26
05:49 am
gmab
Genmab A/S (GMAB) was upgraded by Truist Financial Corporation to "strong-buy".
Low
Report
Genmab A/S (GMAB) was upgraded by Truist Financial Corporation to "strong-buy".
3/20
07:25 am
gmab
Genmab And Lundbeck Amlenetug Data Adds Nuance To Valuation Debate [Yahoo! Finance]
Low
Report
Genmab And Lundbeck Amlenetug Data Adds Nuance To Valuation Debate [Yahoo! Finance]
3/19
03:19 pm
gmab
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab [Yahoo! Finance]
Low
Report
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab [Yahoo! Finance]
3/17
11:11 pm
gmab
Genmab A/S Touts Strong 2025, Teases Catalyst-Heavy 2026 With Potential 2027 Launches [Yahoo! Finance]
Low
Report
Genmab A/S Touts Strong 2025, Teases Catalyst-Heavy 2026 With Potential 2027 Launches [Yahoo! Finance]
3/11
02:57 pm
gmab
Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/2
09:27 am
gmab
Genmab A/S (GMAB) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $40.00 price target on the stock.
Low
Report
Genmab A/S (GMAB) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $40.00 price target on the stock.
3/2
09:12 am
gmab
Transactions in Connection with Share Buy-back Program [Yahoo! Finance]
Low
Report
Transactions in Connection with Share Buy-back Program [Yahoo! Finance]
2/28
07:02 pm
gmab
Is Genmab (CPSE:GMAB) Pricing Look Attractive After Recent Share Price Weakness [Yahoo! Finance]
Low
Report
Is Genmab (CPSE:GMAB) Pricing Look Attractive After Recent Share Price Weakness [Yahoo! Finance]
2/28
07:38 am
gmab
Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Weakness [Yahoo! Finance]
Low
Report
Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Weakness [Yahoo! Finance]
2/27
03:34 pm
gmab
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab [Yahoo! Finance]
Low
Report
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab [Yahoo! Finance]
2/25
11:04 am
gmab
Genmab to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Genmab to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/24
03:40 pm
gmab
Capital Increase in Genmab as a Result of Employee Warrant Exercise [Yahoo! Finance]
Low
Report
Capital Increase in Genmab as a Result of Employee Warrant Exercise [Yahoo! Finance]
2/23
12:39 pm
gmab
Genmab A/S (NASDAQ:GMAB) had its price target lowered by analysts at Guggenheim from $45.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
Genmab A/S (NASDAQ:GMAB) had its price target lowered by analysts at Guggenheim from $45.00 to $40.00. They now have a "buy" rating on the stock.
2/21
05:42 am
gmab
Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales [Yahoo! Finance]
Low
Report
Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales [Yahoo! Finance]
2/20
10:39 am
gmab
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons [Yahoo! Finance]
Low
Report
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons [Yahoo! Finance]
2/20
09:34 am
gmab
Novo Nordisk nominates three new board directors, two with pharma experience [Seeking Alpha]
Low
Report
Novo Nordisk nominates three new board directors, two with pharma experience [Seeking Alpha]
2/18
09:22 am
gmab
Notice to Convene the Annual General Meeting of Genmab A/S [Yahoo! Finance]
Low
Report
Notice to Convene the Annual General Meeting of Genmab A/S [Yahoo! Finance]